A-Textbook-of-Clinical-Pharmacology-and-Therapeutics-5th-edition

Recommendations

Info

PART IX SELECTIVE TOXICITY
This page intentionally left blank
Page 2 and 3:
A Textbook of Clinical Pharmacology
Page 4 and 5:
A Textbook of Clinical Pharmacology
Page 6 and 7:
This fifth edition is dedicated to
Page 8 and 9:
CONTENTS FOREWORD PREFACE ACKNOWLED
Page 10 and 11:
PREFACE Clinical pharmacology is th
Page 12 and 13:
PART I GENERAL PRINCIPLES
Page 14 and 15:
CHAPTER 1 INTRODUCTION TO THERAPEUT
Page 16 and 17:
SCIENTIFIC BASIS OF USE OF DRUGS IN
Page 18 and 19:
AGONISTS 7 100 100 Effect (%) Effec
Page 20 and 21:
SLOW PROCESSES 9 100 2 Dose ratio -
Page 22 and 23:
CHAPTER 3 PHARMACOKINETICS ● Intr
Page 24 and 25:
REPEATED (MULTIPLE) DOSING 13 In re
Page 26 and 27:
NON-LINEAR (‘DOSE-DEPENDENT’) P
Page 28 and 29:
CHAPTER 4 DRUG ABSORPTION AND ROUTE
Page 30 and 31:
ROUTES OF ADMINISTRATION 19 ROUTES
Page 32 and 33:
ROUTES OF ADMINISTRATION 21 Transde
Page 34 and 35:
ROUTES OF ADMINISTRATION 23 FURTHER
Page 36 and 37:
PHASE II METABOLISM (TRANSFERASE RE
Page 38 and 39:
ENZYME INDUCTION 27 and lorazepam.
Page 40 and 41:
METABOLISM OF DRUGS BY INTESTINAL O
Page 42 and 43:
CHAPTER 6 RENAL EXCRETION OF DRUGS
Page 44 and 45:
ACTIVE TUBULAR REABSORPTION 33 ACTI
Page 46 and 47:
RENAL DISEASE 35 DISTRIBUTION Drug
Page 48 and 49:
LIVER DISEASE 37 Detailed recommend
Page 50 and 51:
THYROID DISEASE 39 DIGOXIN Myxoedem
Page 52 and 53:
CHAPTER 8 THERAPEUTIC DRUG MONITORI
Page 54 and 55:
DRUGS FOR WHICH THERAPEUTIC DRUG MO
Page 56 and 57:
CHAPTER 9 DRUGS IN PREGNANCY ● In
Page 58 and 59:
PHARMACOKINETICS IN PREGNANCY 47 va
Page 60 and 61:
PRESCRIBING IN PREGNANCY 49 an anti
Page 62 and 63:
PRESCRIBING IN PREGRANCY 51 Case hi
Page 64 and 65:
BREAST-FEEDING 53 METABOLISM At bir
Page 66 and 67:
RESEARCH 55 lifelong effects as a r
Page 68 and 69:
PHARMACODYNAMIC CHANGES 57 DISTRIBU
Page 70 and 71:
EFFECT OF DRUGS ON SOME MAJOR ORGAN
Page 72 and 73:
RESEARCH 61 FURTHER READING Dhesi J
Page 74 and 75:
ADVERSE DRUG REACTION MONITORING/SU
Page 76 and 77:
ADVERSE DRUG REACTION MONITORING/SU
Page 78 and 79:
PREVENTION OF ALLERGIC DRUG REACTIO
Page 80 and 81:
EXAMPLES OF ALLERGIC AND OTHER ADVE
Page 82 and 83:
CHAPTER 13 DRUG INTERACTIONS ● In
Page 84 and 85:
HARMFUL INTERACTIONS 73 Response Re
Page 86 and 87:
HARMFUL INTERACTIONS 75 Table 13.1:
Page 88 and 89:
HARMFUL INTERACTIONS 77 Table 13.5:
Page 90 and 91:
CHAPTER 14 PHARMACOGENETICS ● Int
Page 92 and 93:
GENETIC INFLUENCES ON DRUG METABOLI
Page 94 and 95:
INHERITED DISEASES THAT PREDISPOSE
Page 96 and 97:
INHERITED DISEASES THAT PREDISPOSE
Page 98 and 99:
CLINICAL TRIALS 87 • Discovery
Page 100 and 101:
CLINICAL DRUG DEVELOPMENT 89 Too ma
Page 102 and 103:
GLOBALIZATION 91 ETHICS COMMITTEES
Page 104 and 105:
CELL-BASED AND RECOMBINANT DNA THER
Page 106 and 107:
HUMAN STEM CELL THERAPY 95 duration
Page 108 and 109:
CHAPTER 17 ALTERNATIVE MEDICINES: H
Page 110 and 111:
SOY 99 A case report has suggested
Page 112 and 113:
MISCELLANEOUS HERBS 101 including h
Page 114 and 115:
PART II THE NERVOUS SYSTEM
Page 116 and 117:
CHAPTER 18 HYPNOTICS AND ANXIOLYTIC
Page 118 and 119:
ANXIETY 107 and daytime sleeping sh
Page 120 and 121:
ANXIETY 109 Key points • Insomnia
Page 122 and 123:
SCHIZOPHRENIA 111 Box 19.1: Dopamin
Page 124 and 125:
SCHIZOPHRENIA 113 The Boston Collab
Page 126 and 127:
BEHAVIOURAL EMERGENCIES 115 Oral me
Page 128 and 129:
DEPRESSIVE ILLNESSES AND ANTIDEPRES
Page 130 and 131:
DEPRESSIVE ILLNESSES AND ANTIDEPRES
Page 132 and 133:
LITHIUM, TRYPTOPHAN AND ST JOHN’S
Page 134 and 135:
SPECIAL GROUPS 123 Case history A 4
Page 136 and 137:
PARKINSON’S SYNDROME AND ITS TREA
Page 138 and 139:
PARKINSON’S SYNDROME AND ITS TREA
Page 140 and 141:
MYASTHENIA GRAVIS 129 CHOREA The γ
Page 142 and 143:
ALZHEIMER’S DISEASE 131 Cholinerg
Page 144 and 145:
CHAPTER 22 ANTI-EPILEPTICS ● Intr
Page 146 and 147:
GENERAL PRINCIPLES OF TREATMENT OF
Page 148 and 149:
GENERAL PRINCIPLES OF TREATMENT OF
Page 150 and 151:
WITHDRAWAL OF ANTI-EPILEPTIC DRUGS
Page 152 and 153:
FEBRILE CONVULSIONS 141 Case histor
Page 154 and 155:
DRUGS USED FOR MIGRAINE PROPHYLAXIS
Page 156 and 157:
CHAPTER 24 ANAESTHETICS AND MUSCLE
Page 158 and 159:
INHALATIONAL ANAESTHETICS 147 is th
Page 160 and 161:
SUPPLEMENTARY DRUGS 149 • Respira
Page 162 and 163:
MUSCLE RELAXANTS 151 NON-DEPOLARIZI
Page 164 and 165:
LOCAL ANAESTHETICS 153 have also pr
Page 166 and 167:
CHAPTER 25 ANALGESICS AND THE CONTR
Page 168 and 169:
DRUGS USED TO TREAT MILD OR MODERAT
Page 170 and 171:
OPIOIDS 159 Key points Drugs for mi
Page 172 and 173:
OPIOIDS 161 increases, correlating
Page 174 and 175:
MANAGEMENT OF POST-OPERATIVE PAIN 1
Page 176 and 177:
PART III THE MUSCULOSKELETAL SYSTEM
Page 178 and 179:
CHAPTER 26 ANTI-INFLAMMATORY DRUGS
Page 180 and 181:
DISEASE-MODIFYING ANTIRHEUMATIC DRU
Page 182 and 183:
HYPERURICAEMIA AND GOUT 171 • Sto
Page 184 and 185:
HYPERURICAEMIA AND GOUT 173 Pharmac
Page 186 and 187:
PART IV THE CARDIOVASCULAR SYSTEM
Page 188 and 189:
CHAPTER 27 PREVENTION OF ATHEROMA:
Page 190 and 191:
PREVENTION OF ATHEROMA 179 responsi
Page 192 and 193:
DRUGS USED TO TREAT DYSLIPIDAEMIA 1
Page 194 and 195:
DRUGS USED TO TREAT DYSLIPIDAEMIA 1
Page 196 and 197:
CHAPTER 28 HYPERTENSION ● Introdu
Page 198 and 199:
DRUGS USED TO TREAT HYPERTENSION 18
Page 200 and 201:
Page 202 and 203:
Page 204 and 205:
OTHER ANTIHYPERTENSIVE DRUGS 193 Ke
Page 206 and 207:
OTHER ANTIHYPERTENSIVE DRUGS 195 Ca
Page 208 and 209:
MANAGEMENT OF STABLE ANGINA 197 Ass
Page 210 and 211:
MANAGEMENT OF UNSTABLE CORONARY DIS
Page 212 and 213:
DRUGS USED IN ISCHAEMIC HEART DISEA
Page 214 and 215:
DRUGS USED IN ISCHAEMIC HEART DISEA
Page 216 and 217:
ANTICOAGULANTS 205 Intrinsic pathwa
Page 218 and 219:
ANTICOAGULANTS 207 that the pharmac
Page 220 and 221:
ANTICOAGULANTS IN PREGNANCY AND PUE
Page 222 and 223:
CHAPTER 31 HEART FAILURE ● Introd
Page 224 and 225:
DRUGS FOR HEART FAILURE 213 The dru
Page 226 and 227:
DRUGS FOR HEART FAILURE 215 therape
Page 228 and 229:
CHAPTER 32 CARDIAC DYSRHYTHMIAS ●
Page 230 and 231:
CARDIOPULMONARY RESUSCITATION AND C
Page 232 and 233:
TREATMENT OF OTHER SPECIFIC DYSRHYT
Page 234 and 235:
SELECTED ANTI-DYSRHYTHMIC DRUGS 223
Page 236 and 237:
Page 238 and 239:
Page 240 and 241:
Page 242 and 243:
PART V THE RESPIRATORY SYSTEM
Page 244 and 245:
CHAPTER 33 THERAPY OF ASTHMA, CHRON
Page 246 and 247:
CHRONIC BRONCHITIS AND EMPHYSEMA 23
Page 248 and 249:
DRUGS USED TO TREAT ASTHMA AND CHRO
Page 250 and 251:
DRUGS USED TO TREAT ASTHMA AND CHRO
Page 252 and 253:
RESPIRATORY FAILURE 241 use in asth
Page 254 and 255:
DRUG-INDUCED PULMONARY DISEASE 243
Page 256 and 257:
PART VI THE ALIMENTARY SYSTEM
Page 258 and 259:
CHAPTER 34 ALIMENTARY SYSTEM AND LI
Page 260 and 261:
PEPTIC ULCERATION 249 • With rega
Page 262 and 263:
PEPTIC ULCERATION 251 Ranitidine ha
Page 264 and 265:
ANTI-EMETICS 253 Vestibular stimula
Page 266 and 267:
INFLAMMATORY BOWEL DISEASE 255 cort
Page 268 and 269:
CONSTIPATION 257 • in hepatocellu
Page 270 and 271:
PANCREATIC INSUFFICIENCY 259 Ciprof
Page 272 and 273:
LIVER DISEASE 261 withdrawal), smal
Page 274 and 275:
DRUGS THAT MODIFY APPETITE 263 Tabl
Page 276 and 277:
CHAPTER 35 VITAMINS AND TRACE ELEME
Page 278 and 279:
VITAMIN C(ASCORBIC ACID) 267 dinucl
Page 280 and 281:
TRACE ELEMENTS 269 Table 35.1: Comm
Page 282 and 283: PART VII FLUIDS AND ELECTROLYTES
Page 284 and 285: CHAPTER 36 NEPHROLOGICAL AND RELATE
Page 286 and 287: DIURETICS 275 Key points Diuretics
Page 288 and 289: VOLUME DEPLETION 277 is sometimes c
Page 290 and 291: DRUGS THAT AFFECT THE BLADDER AND G
Page 292 and 293: DRUGS THAT AFFECT THE BLADDER AND G
Page 294 and 295: PART VIII THE ENDOCRINE SYSTEM
Page 296 and 297: CHAPTER 37 DIABETES MELLITUS ● In
Page 298 and 299: DRUGS USED TO TREAT DIABETES MELLIT
Page 304 and 305: ANTITHYROID DRUGS 293 deficiency. P
Page 306 and 307: SPECIAL SITUATIONS 295 fertility. I
Page 308 and 309: CHAPTER 39 CALCIUM METABOLISM ● I
Page 310 and 311: BISPHOSPHONATES 299 effective in li
Page 312 and 313: CINACALCET 301 Further reading Bloc
Page 314 and 315: ADRENAL CORTEX 303 Table 40.1: Acti
Page 316 and 317: ADRENAL MEDULLA 305 injection may b
Page 318 and 319: CHAPTER 41 REPRODUCTIVE ENDOCRINOLO
Page 320 and 321: FEMALE REPRODUCTIVE ENDOCRINOLOGY 3
Page 322 and 323: FEMALE REPRODUCTIVE ENDOCRINOLOGY 3
Page 324 and 325: MALE REPRODUCTIVE ENDOCRINOLOGY 313
Page 326 and 327: MALE REPRODUCTIVE ENDOCRINOLOGY 315
Page 328 and 329: ANTERIOR PITUITARY HARMONES AND REL
Page 330 and 331: POSTERIOR PITUITARY HARMONES 319 FU
Page 334 and 335: CHAPTER 43 ANTIBACTERIAL DRUGS ●
Page 336 and 337: COMMONLY PRESCRIBED ANTIBACTERIAL D
Page 346 and 347: PRINCIPLES OF MANAGEMENT OF MYCOBAC
Page 348 and 349: FIRST-LINE DRUGS IN TUBERCULOSIS TH
Page 350 and 351: MYCOBACTERIUM LEPRAE INFECTION 339
Page 352 and 353: ANTIFUNGAL DRUG THERAPY 341 POLYENE
Page 354 and 355: ANTIFUNGAL DRUG THERAPY 343 therapy
Page 356 and 357: ANTIVIRAL DRUG THERAPY (EXCLUDING A
Page 358 and 359: ANTIVIRAL DRUG THERAPY (EXCLUDING A
Page 360 and 361: INTERFERONS AND ANTIVIRAL HEPATITIS
Page 362 and 363: CHAPTER 46 HIV AND AIDS ● Introdu
Page 364 and 365: ANTI-HIV DRUGS 353 Table 46.1: Exam
Page 366 and 367: ANTI-HIV DRUGS 355 NON-NUCLEOSIDE A
Page 368 and 369: OPPORTUNISTIC INFECTIONS IN HIV-1-S
Page 370 and 371: ANTI-HERPES VIRUS THERAPY 359 salva
Page 372 and 373: CHAPTER 47 MALARIA AND OTHER PARASI
Page 374 and 375: MALARIA 363 Pharmacokinetics Chloro
Page 376 and 377: HELMINTHIC INFECTION 365 Table 47.2
Page 378 and 379: CHAPTER 48 CANCER CHEMOTHERAPY ●
Page 380 and 381: COMMON COMPLICATIONS OF CANCER CHEM
Page 382 and 383:
DRUGS USED IN CANCER CHEMOTHERAPY 3
Page 384 and 385:
Page 386 and 387:
Page 388 and 389:
Page 390 and 391:
Page 392 and 393:
Page 394 and 395:
Page 396 and 397:
Page 398 and 399:
PART X HAEMATOLOGY
Page 400 and 401:
CHAPTER 49 ANAEMIA AND OTHER HAEMAT
Page 402 and 403:
HAEMATINICS - IRON, VITAMIN B 12 AN
Page 404 and 405:
HAEMATOPOIETIC GROWTH FACTORS 393 S
Page 406 and 407:
IDIOPATHIC THROMBOCYTOPENIC PURPURA
Page 408 and 409:
PART XI IMMUNOPHARMACOLOGY
Page 410 and 411:
CHAPTER 50 CLINICAL IMMUNOPHARMACOL
Page 412 and 413:
IMMUNOSUPPRESSIVE AGENTS 401 Ag Ant
Page 414 and 415:
IMMUNOSUPPRESSIVE AGENTS 403 Table
Page 416 and 417:
CHEMICAL MEDIATORS OF THE IMMUNE RE
Page 418 and 419:
IMMUNOGLOBULINS AS THERAPY 407 DRUG
Page 420 and 421:
PART XII THE SKIN
Page 422 and 423:
CHAPTER 51 DRUGS AND THE SKIN ● I
Page 424 and 425:
DERMATITIS (ECZEMA) 413 Avoid preci
Page 426 and 427:
PSORIASIS 415 Emollients Improving
Page 428 and 429:
ADVERSE DRUG REACTIONS INVOLVING TH
Page 430 and 431:
ADVERSE DRUG REACTIONS INVOLVING TH
Page 432 and 433:
PART XIII THE EYE
Page 434 and 435:
CHAPTER 52 DRUGS AND THE EYE ● In
Page 436 and 437:
DRUGS USED TO CONSTRICT THE PUPIL A
Page 438 and 439:
DRUGS USED TO TREAT INFLAMMATORY DI
Page 440 and 441:
CONTACT LENS WEARERS 429 Table 52.6
Page 442 and 443:
PART XIV CLINICAL TOXICOLOGY
Page 444 and 445:
CHAPTER 53 DRUGS AND ALCOHOL ABUSE
Page 446 and 447:
OPIOID/NARCOTIC ANALGESICS 435 Tabl
Page 448 and 449:
DRUGS THAT ALTER PERCEPTION 437 whi
Page 450 and 451:
CENTRAL DEPRESSANTS 439 Peak plasma
Page 452 and 453:
CENTRAL DEPRESSANTS 441 Key points
Page 454 and 455:
MISCELLANEOUS 443 FURTHER READING G
Page 456 and 457:
INTENTIONAL SELF-POISONING 445 Tabl
Page 458 and 459:
INTENTIONAL SELF-POISONING 447 Tabl
Page 460 and 461:
CRIMINAL POISONING 449 Commission o
Page 462 and 463:
INDEX Note: Page numbers in italics
Page 464 and 465:
INDEX 453 atrial fibrillation 217,
Page 466 and 467:
INDEX 455 Cushing’s syndrome 302
Page 468 and 469:
INDEX 457 5-fluorouracil 375-6 fluo
Page 470 and 471:
INDEX 459 children 54 diazepam 108
Page 472 and 473:
INDEX 461 non-steroidal anti-inflam
Page 474 and 475:
INDEX 463 puberty (male), delay 314
Page 476:
INDEX 465 tolerance 9, 433 benzodia
show all

A-Textbook-of-Clinical-Pharmacology-and-Therapeutics-5th-edition

You also want an ePaper? Increase the reach of your titles

Delete template?

Save as template?